The company’s Cryo-Vacc innovations have the potential to make a contribution to the company’s bottom line, CEO Stefano Marani tells The Africa Report. While it’s too early to judge how much Cryo-Vacc can add to profit, the patented invention “has the potential to be quite material in the near future,” Marani says in Johannesburg.
Getting sufficient Covid-19 doses for Africa is only part of the problem. The need for vaccines, such as that developed by Pfizer, to be stored at ultra-low temperatures creates a major logistical problem, especially in moving the vaccines to rural areas.
Marani drew up the Cryo-Vacc concept, which was then put into practice by the company’s engineering team. Vaccines can be stored at -70°C for up to 25 days, and during that time, they are completely mobile. No electricity is needed. The solution exists in two forms. Liquid nitrogen is used for ground-based
There's more to this story
Get unlimited access to our exclusive journalism and features today. Our award-winning team of correspondents and editors report from over 54 African countries, from Cape Town to Cairo, from Abidjan to Abuja to Addis Ababa. Africa. Unlocked.
cancel anytime
Already a a subscriber Sign In
